ArticleScience progress
Impact of COVID-19 on the prevalence of oral and maxillofacial disorders: A retrospective cohort study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThe COVID-19 pandemic has impacted various health conditions. Emerging evidence suggests that COVID-19 may trigger or exacerbate oral and maxillofacial conditions, yet data from Iraq and the broader Middle East remain limited. This retrospective cohort study, conducted at the Laboratory of Oral Pathology, College of Dentistry, University of Baghdad, explores potential links between COVID-19 infection and maxillofacial disorders.MethodsThis was a retrospective cohort study using data from the Laboratory of Oral Pathology, College of Dentistry, University of Baghdad. Cases were divided into pre-COVID-19 and post-COVID-19 periods. Chi-square tests assessed differences in oral pathologies incidence, while logistic regression analyzed associations with COVID-19 status and corticosteroid use.ResultsMucormycosis cases demonstrated a significant increase from 3 (pre-COVID-19) to 23 (post-COVID-19), with 65.22% of post-COVID-19 patients testing COVID-19-positive. A significant increase in mucormycosis severity was observed after COVID-19 (χ² = 14.24, p = 0.0026). Logistic regression identified age (coefficient 0.8738) as having a significant association with severe mucormycosis, while COVID-19 status (coefficient 0.1272) exerted a lesser effect. Sjögren's syndrome increased from 15 to 25 cases, with a model area under the curve of 0.8, indicating substantial ability to distinguish symptom changes pre- vs. post-COVID-19.ConclusionThe findings suggest that the pandemic has considerably impacted the incidence and severity of mucormycosis and Sjögren's syndrome. Older age and COVID-19 positivity may be key drivers of severe mucormycosis, whereas COVID-19 infection appeared to exacerbate Sjögren's syndrome symptoms. These results underscore the importance of vigilant monitoring and targeted therapeutic strategies for managing oral and maxillofacial conditions during and after viral pandemics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.